A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy

Berrak S. G., Ozdemir N., Bakirci N., Turkkan E., Canpolat C., Beker B., ...More

SUPPORTIVE CARE IN CANCER, vol.15, no.10, pp.1163-1168, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 10
  • Publication Date: 2007
  • Doi Number: 10.1007/s00520-007-0242-y
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1163-1168
  • Keywords: granisetron, antiemetic, efficacy, chemotherapy, dose comparison, RECEPTOR ANTAGONISTS, ANTIEMETIC THERAPY, PROPHYLAXIS, EFFICACY, CANCER, DEXAMETHASONE, SAFETY
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No


Background Granisetron is a safe and effective prophylaxis for nausea and vomiting associated with moderate to highly emetogenic chemotherapy. Few trials have been conducted to determine the optimal effective dose of granisetron in children with cancer. The objective of this report was to compare two doses of granisetron in patients with optic pathway tumors receiving moderately emetogenic doses of carboplatin.